Latest News About Replimune Group

Here are the latest publicly available updates on Replimune Group as of May 2026:

• FDA update on RP1: Replimune reported that the FDA issued a complete response letter (CRL) for the RP1 plus nivolumab program in advanced melanoma, with the agency declining regulatory flexibility and indicating the need for additional data or pathway reconsideration. This development has prompted the company to reassess its regulatory strategy and manufacturing footprint in the U.S. [Source discussions around April 2026 CRL implications include summaries from financial news outlets and the company’s quarterly updates.]

• Corporate and financing updates following the CRL: In connection with the RP1 regulatory setback, Replimune disclosed ongoing efforts to adjust corporate plans, including manufacturing scale-back considerations and exploring accelerated approval pathways or alternative development strategies. The company highlighted discussions with lenders and potential post-approval funding arrangements to support continued operations and liquidity.

• Q2/Q3 2025–2026 financials and clinical program status: Replimune continued to advance its broader portfolio, including RP2 REVEAL for metastatic uveal melanoma and other RP1-related activities, while maintaining a cash runway through late 2025 into 2026. The company reported cash on hand and net losses typical for a late-stage biopharma company pursuing multiple cancer programs, with emphasis on data readouts and regulatory interactions.

• Historical context from 2024–late 2025: Earlier updates noted that the FDA accepted the BLA resubmission for RP1 with a PDUFA target date in 2026, and that IGNYTE trial data were central to the program’s potential, with ongoing presentations and trial activity described in quarterly results. These historical milestones provide context for the 2026 CRL outcome.

• Regulatory and filing documents: Replimune’s periodic 8-K filings and SEC disclosures during 2024–2025 documented progress toward a BLA submission for RP1 and updates on clinical activity across RP1 plus nivolumab and RP2 REVEAL, as well as discussions with the FDA about path forward. These documents are primary sources for the regulatory timeline.

If you’d like, I can search for the most current press releases or SEC filings to provide precise dates, extract key quotes, or summarize how the CRL specifically affects the company’s therapeutic roadmap and workforce plans. I can also create a concise timeline or a chart of the RP1 program milestones to visualize the regulatory trajectory.